- Home
- PRLD vs PLUR Comparison
PRLD vs PLUR Comparison
Compare PRLD & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- PLUR
- Stock Information
- Founded
- PRLD 2016
- PLUR 2001
- Country
- PRLD United States
- PLUR Israel
- Employees
- PRLD N/A
- PLUR N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- PLUR Health Care
- Exchange
- PRLD Nasdaq
- PLUR Nasdaq
- Market Cap
- PRLD 48.6M
- PLUR 41.9M
- IPO Year
- PRLD 2020
- PLUR N/A
- Fundamental
- Price
- PRLD $0.82
- PLUR $5.32
- Analyst Decision
- PRLD Strong Buy
- PLUR Strong Buy
- Analyst Count
- PRLD 2
- PLUR 1
- Target Price
- PRLD $4.50
- PLUR $12.00
- AVG Volume (30 Days)
- PRLD 121.2K
- PLUR 14.4K
- Earning Date
- PRLD 08-11-2025
- PLUR 09-17-2025
- Dividend Yield
- PRLD N/A
- PLUR N/A
- EPS Growth
- PRLD N/A
- PLUR N/A
- EPS
- PRLD N/A
- PLUR N/A
- Revenue
- PRLD $7,000,000.00
- PLUR $1,034,000.00
- Revenue This Year
- PRLD N/A
- PLUR $472.39
- Revenue Next Year
- PRLD N/A
- PLUR $254.29
- P/E Ratio
- PRLD N/A
- PLUR N/A
- Revenue Growth
- PRLD N/A
- PLUR 203.23
- 52 Week Low
- PRLD $0.61
- PLUR $3.33
- 52 Week High
- PRLD $6.80
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- PRLD 44.66
- PLUR 54.12
- Support Level
- PRLD $0.81
- PLUR $5.05
- Resistance Level
- PRLD $1.00
- PLUR $5.49
- Average True Range (ATR)
- PRLD 0.08
- PLUR 0.31
- MACD
- PRLD 0.00
- PLUR -0.02
- Stochastic Oscillator
- PRLD 20.48
- PLUR 80.38
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.